• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cell . SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2

tetano

Editor, Senior Moderator
Cell


. 2021 Jun 8;S0092-8674(21)00706-6.
doi: 10.1016/j.cell.2021.06.005. Online ahead of print.
SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2


Fatima Amanat[SUP] 1 [/SUP], Mahima Thapa[SUP] 2 [/SUP], Tinting Lei[SUP] 2 [/SUP], Shaza M Sayed Ahmed[SUP] 2 [/SUP], Daniel C Adelsberg[SUP] 3 [/SUP], Juan Manuel Carreño[SUP] 3 [/SUP], Shirin Strohmeier[SUP] 3 [/SUP], Aaron J Schmitz[SUP] 2 [/SUP], Sarah Zafar[SUP] 3 [/SUP], Julian Q Zhou[SUP] 4 [/SUP], Willemijn Rijnink[SUP] 3 [/SUP], Hala Alshammary[SUP] 3 [/SUP], Nicholas Borcherding[SUP] 2 [/SUP], Ana Gonzalez Reiche[SUP] 5 [/SUP], Komal Srivastava[SUP] 3 [/SUP], Emilia Mia Sordillo[SUP] 6 [/SUP], Harm van Bakel[SUP] 7 [/SUP], Personalized Virology Initiative; Jackson S Turner[SUP] 2 [/SUP], Goran Bajic[SUP] 8 [/SUP], Viviana Simon[SUP] 9 [/SUP], Ali H Ellebedy[SUP] 10 [/SUP], Florian Krammer[SUP] 11 [/SUP]



Collaborators, Affiliations

Abstract

In this study we profiled vaccine-induced polyclonal antibodies as well as plasmablast-derived mAbs from individuals who received SARS-CoV-2 spike mRNA vaccine. Polyclonal antibody responses in vaccinees were robust and comparable to or exceeded those seen after natural infection. However, the ratio of binding to neutralizing antibodies after vaccination was greater than that after natural infection and, at the monoclonal level, we found that the majority of vaccine-induced antibodies did not have neutralizing activity. We also found a co-dominance of mAbs targeting the NTD and RBD of SARS-CoV-2 spike and an original antigenic-sin like backboost to spikes of seasonal human coronaviruses OC43 and HKU1. Neutralizing activity of NTD mAbs but not RBD mAbs against a clinical viral isolate carrying E484K as well as extensive changes in the NTD was abolished, suggesting that a proportion of vaccine-induced RBD binding antibodies may provide substantial protection against viral variants carrying single E484K RBD mutations.

Keywords: NTD; RBD; SARS-CoV-2; mAbs; mRNA vaccination; plasmablasts; spike.
 
Back
Top Bottom